KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Consolidated Net Income (2017 - 2026)

Aurinia Pharmaceuticals filings provide 8 years of Consolidated Net Income readings, the most recent being $210.8 million for Q4 2025.

  • On a quarterly basis, Consolidated Net Income rose 14650.87% to $210.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $287.2 million, a 4893.01% increase, with the full-year FY2025 number at $287.2 million, up 4892.3% from a year prior.
  • Consolidated Net Income hit $210.8 million in Q4 2025 for Aurinia Pharmaceuticals, up from $31.6 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $210.8 million in Q4 2025 to a low of -$50.4 million in Q1 2021.
  • Median Consolidated Net Income over the past 5 years was -$12.5 million (2023), compared with a mean of -$3.7 million.
  • Biggest five-year swings in Consolidated Net Income: tumbled 94.27% in 2021 and later soared 14650.87% in 2025.
  • Aurinia Pharmaceuticals' Consolidated Net Income stood at -$33.3 million in 2021, then increased by 21.84% to -$26.0 million in 2022, then decreased by 3.15% to -$26.9 million in 2023, then skyrocketed by 105.32% to $1.4 million in 2024, then soared by 14650.87% to $210.8 million in 2025.
  • The last three reported values for Consolidated Net Income were $210.8 million (Q4 2025), $31.6 million (Q3 2025), and $21.5 million (Q2 2025) per Business Quant data.